NCT06849791View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy Volunteer
Interventions
DRUG

ABBV-932

Oral Capsule

DRUG

ABBV-932

Oral tablet

Trial Locations (1)

60030

Acpru /Id# 266649, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY